allogeneic fibroblasts

Cell therapyexperimental

Clinical trial activity

6 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
4
Phase 3
3
Phase 4
0

Earliest trial started Jul 31, 2005 (NCT00232973)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetTissue restoration

    Tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07219654Phase 2Nov 30, 2025Tego Science, Inc.
NCT06533540Phase 1Dec 31, 2024Tego Science, Inc.
NCT06414005Phase 2/Phase 3 (Phase 3)Apr 15, 2024Seoul National University, Tego Science, Inc.
NCT06197789Phase 3Aug 18, 2021Kyungpook University, Tego Science, Inc.
NCT04470167Phase 1/Phase 2 (Phase 2)Oct 26, 2020Seoul National University, Tego Science, Inc.
NCT00232973Phase 3Jul 31, 2005Intercytex
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tego Science, Inc.For profit5532020
Seoul National UniversityAcademic/Hospital2022020
IntercytexFor profit1112005
Kyungpook UniversityAcademic/Hospital1012021
4 organizations
Page 1 / 1